Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal StudyHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal StudyPriya NigamBenzingaJanuary 7, 2020ReblogShareTweetShareIveric Bio Inc’s (NASDAQ: ISEE) lead asset, Zimura, could begin a pivotal clinical study in the geographic atrophy market in the quarter, according to Wedbush.The AnalystWedbush’s David Nierengarten initiated coverage of Iveric Bio with an Outperform rating and a price target of $13.The ThesisGeographic atrophy is estimated to represent a market opportunity of over $1 billion, with the current patient population at more than 1 million, Nierengarten said in the note.In October, Iveric Bio had announced Zimura showed positive results in slowing the growth of lesions in its Phase 2 study. The company’s lead asset is also being investigated in Stargardt disease and data from this study could come as early as in the back half of 2002, the analyst noted.Nierengarten expects more details of the trial design for Zimura’s pivotal study to be disclosed at Iveric Bio’s R&D investor symposium on Jan. 14.He further wrote, “The company is also building a portfolio of gene therapy candidates, with the first program in autosomal dominant retinitis pigmentosa (adRP) likely to enter the clinic late this year.”Price ActionShares of Iveric Bio traded 4.2% higher to $8.46 at the time of publishing on Tuesday.Latest Ratings for ISEE Date Firm Action From To
Jan 2020
Initiates Coverage On
Outperform
View More Analyst Ratings for ISEE
View the Latest Analyst Ratings0See more from BenzingaXP Analysts Stay On Sidelines Despite Brazilian Brokerage's Bright ProspectsBank Of America Upgrades Life Storage On Greater Supply VisibilityBank Of America Downgrades CubeSmart On Intensifying Supply Pressures© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoUsing Scenario Analysis for Your PortfolioSmartAsset'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoIBD's Investing Podcast: How To Make More Money In The Stock Market With Stock ChartsInvestor's Business DailyDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance